Resources Repository
-
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Policy/Regulation | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Test Performance | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Policy/Regulation | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Health Systems | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Policy/Regulation | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ReviewPublication 2021Considerations for Diagnostic COVID-19 Tests
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic …
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic test manufacturers to create, validate, and implement testing methods. This review discusses the pivotal role of diagnostic tests during the pandemic's first global wave, highlighting the challenges in technology and implementation experienced early on. The study also offers insights for enhancing the use of diagnostics, especially syndromic ones, should there be future spikes or regional outbreaks of COVID-19. The overarching…
Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology | North America -
ReviewPublication 2022Rapid, Point-of-Care Antigen Tests for Diagnosis of SARS-CoV-2 Infection
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, …
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, differentiating results between symptomatic and asymptomatic individuals. Using data from 155 study cohorts, the study found that the sensitivity of antigen tests was generally higher for symptomatic individuals, especially during the first week after symptom onset, due to higher viral loads. For example, average sensitivity was higher in symptomatic (73.0%) compared to asymptomatic participants (54.7). Average sensitivity was higher in…
Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology | North America -
ReviewPublication 2022Significance of Advanced COVID-19 Diagnostic Testing in Pandemic Control Measures
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant …
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant efforts to combat the highly transmissible SARS-CoV-2 virus. Despite substantial progress in vaccines and treatments, leading to lower hospitalization and death rates, the virus has continued to evolve, primarily through mutations. From the onset, diagnostic tests have been crucial in identifying and controlling the virus spread. The scientific world has pioneered various diagnostic techniques, including nucleic acid, antigen, and antibody-based…
Infectious Diseases | Test Performance | Health Systems | Clinical Care | Health/Medicine | Science/Technology | North America -
ReviewPublication 2022Diagnostics for COVID-19: Moving from Pandemic Response to Control
Diagnostics are essential in managing the COVID-19 pandemic, with three primary methods for detecting SARS-CoV-2 …
Diagnostics are essential in managing the COVID-19 pandemic, with three primary methods for detecting SARS-CoV-2 infections. Each test type remains vital as we shift from responding to controlling the pandemic. Molecular tests, like PCR, are highly precise in identifying viral RNA and are endorsed by the WHO for confirming cases and guiding public health actions. Antigen rapid tests spot viral proteins and, while less accurate than molecular tests, are quicker, more affordable, simpler, and can…
Infectious Diseases | Test Performance | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Decision Analysis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global | Graduate | Doctoral | Professional -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Infectious Diseases | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America